What is Rimexolone
Rimexolone is a corticosteroid that is administered topically to the eye to reduce inflammation during the postoperative period following ocular surgery. It is the first ophthalmic steroid indicated for this condition.
Rimexolone is also indicated for the treatment of anterior uveitis. In clinical studies, 1% rimexolone demonstrated clinical equivalence to 1% prednisolone in reducing uveitic inflammation.
Rimexolone was approved for ophthalmic use by the FDA on December 30, 1994.
A parenteral formulation is under investigation for intra-articular use in patients with rheumatoid arthritis.
Brand Name
Vexol
Indications
- postoperative ocular inflammation
- rheumatoid arthritis
- uveitis
- vernal keratoconjunctivitis
Side Effects
- blurred vision
- cataracts
- corneal edema
- corneal erosion
- dysgeusia
- foreign body sensation
- headache
- hyperemia
- hypotension
- keratitis
- ocular discharge
- ocular hypertension
- ocular infection
- ocular irritation
- ocular pain
- ocular pruritus
- pharyngitis
- photophobia
- rhinitis
- visual impairment
- xerophthalmia
Monitoring Parameters
- intraocular pressure
Contraindications
- breast-feeding
- cataracts
- children
- corticosteroid hypersensitivity
- fungal infection
- glaucoma
- herpes simplex keratitis (dendritic keratitis)
- infants
- infection
- mycobacterial infection
- neonates
- pregnancy
- varicella
- viral infection
- visual disturbance
Interactions
There are no drug interactions associated with Rimexolone products.
